Literature DB >> 8688338

Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population.

M Maynadié1, C Verret, P Moskovtchenko, F Mugneret, T Petrella, D Caillot, P M Carli.   

Abstract

Data on myelodysplastic syndromes (MDS) are seldom collected by cancer registries and unbiased findings from population-based studies remain rare. We report detailed information on MDS in a well-defined French population in the period 1980-1990. The crude incidence rate was 3.2 per 100000 per year and no significant change in incidence was noted in the study period. The sex ratio was 1.9 and the male predominance was present in all age groups. We observed a rise in incidence after 60 years of age but no significant change in incidence of MDS as a whole was observed over the period studied. Refractory anaemia with excess of blasts (RAEB) was the most frequent subtype. Overall 5 year transformation rate of MDS was 31% (+/- 4%) but it was 100% in RAEB in transformation. The observed 5 year survival rate was 23% +/- 3% and the corresponding corrected rate was 33%. The prognosis of RAEB in transformation was worse than the prognosis of other subtypes (P < 0.01). Discrepancies with epidemiological data from other European countries are discussed.

Entities:  

Mesh:

Year:  1996        PMID: 8688338      PMCID: PMC2074591          DOI: 10.1038/bjc.1996.354

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Increasing prevalence of the myelodysplastic syndrome. An international Delphi study.

Authors:  P Reizenstein; L Dabrowski
Journal:  Anticancer Res       Date:  1991 May-Jun       Impact factor: 2.480

2.  Establishing the incidence of myelodysplasia syndrome.

Authors:  M J Phillips; G M Cull; M Ewings
Journal:  Br J Haematol       Date:  1994-12       Impact factor: 6.998

3.  Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity.

Authors:  G Lambertenghi-Deliliers; A Orazi; R Luksch; C Annaloro; D Soligo
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

4.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

5.  Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.

Authors:  G Tricot; C De Wolf-Peeters; B Hendrickx; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-07       Impact factor: 6.998

6.  Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases.

Authors:  H Kerkhofs; J Hermans; H L Haak; C H Leeksma
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

7.  Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors.

Authors:  P Fenaux; J P Jouet; M Zandecki; J L Lai; M Simon; J P Pollet; F Bauters
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

8.  Establishing the incidence of myelodysplastic syndrome.

Authors:  P J Williamson; A R Kruger; P J Reynolds; T J Hamblin; D G Oscier
Journal:  Br J Haematol       Date:  1994-08       Impact factor: 6.998

9.  Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.

Authors:  C Aul; N Gattermann; W Schneider
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

10.  Haematopoietic malignancies in Côte d'Or (France): a population based study.

Authors:  P M Carli; C Milan; A Lange; E Devilliers; H Guy; J Faivre
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

View more
  13 in total

1.  Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).

Authors:  Marc Maynadié; François Girodon; Ines Manivet-Janoray; Morgane Mounier; Francine Mugneret; François Bailly; Bernardine Favre; Denis Caillot; Tony Petrella; Michel Flesch; Paule-Marie Carli
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

3.  Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island.

Authors:  Kumiko Yagisawa; Kiyoshi Okazuka; Ken Toba; Masaru Urushiyama; Takashi Kuroha; Noriko Izumi; Yasuhiko Sibasaki; Masutaka Higashimura; Toshio Yano; Akihito Momoi; Akira Hattori; Ken Momotsu; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2012-02-24       Impact factor: 2.490

Review 4.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 5.  What's all the fuss about? facts and figures about bone marrow failure and conditions.

Authors:  Sudipto Mukherjee; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 6.  Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics.

Authors:  C Aul; A Giagounidis; U Germing
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

Review 7.  The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Authors:  Zaher K Otrock; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Expert Rev Hematol       Date:  2013-02       Impact factor: 2.929

8.  Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.

Authors:  Marc Maynadié; Roberta De Angelis; Rafael Marcos-Gragera; Otto Visser; Claudia Allemani; Carmen Tereanu; Riccardo Capocaccia; Adriano Giacomin; Jean-Michel Lutz; Carmen Martos; Risto Sankila; Tom Børge Johannesen; Arianna Simonetti; Milena Sant
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

9.  The incidence of myelodysplastic syndromes in Western Greece is increasing.

Authors:  Christina Avgerinou; Yannis Alamanos; Panagiotis Zikos; Polyxeni Lampropoulou; Maria Melachrinou; Vassiliki Labropoulou; Ioannis Tavernarakis; Anthi Aktypi; Panagiotis Kaiafas; Christos Raptis; Alexandra Kouraklis; Marina Karakantza; Argiris Symeonidis
Journal:  Ann Hematol       Date:  2013-04-10       Impact factor: 3.673

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.